Compare Honest Company Inc (HNST) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs BIO-TECHNE Corp — how do they compare? Honest Company Inc trades at $4.97 (market cap $529.98M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 21.5× Honest Company Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and BIO-TECHNE Corp for 63 Days on average.
| HNST | TECH | |
|---|---|---|
Market Cap | $529.98M | $11.37B |
Volume | 1,365,795 | 3,153,511 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $72.61 |
52-Week Low | $2.10 | $43.31 |
Typical Hold Time | 39 Days | 63 Days |
Enterprise Value | $433.59M | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $4.93, down 1.99% on the day, with a bearish technical outlook and mixed fundamentals. The company reported Q2 2026 EPS of $0.04, beating expectations, but maintains negative net income margins. Revenue declined to $371.32M in 2025, though cash flow from operations improved to $15.12M. Analyst sentiment is cautious with a $5.30 consensus target, while institutional interest includes recent investments from BlackRock and Deutsche Bank.
The stock faces headwinds from sustained profitability challenges and competitive pressures, but strategic exits and cost reductions show early turnaround signs. Upside potential exists if margin improvements continue, though investors should weigh execution risks against the current valuation premium (P/E 48.83).
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
